99 related articles for article (PubMed ID: 23221734)
21. Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Holman LL; Pal N; Iglesias DA; Soliman PT; Balakrishnan N; Klopp A; Broaddus RR; Fleming ND; Munsell MF; Lu KH; Westin SN
Gynecol Oncol; 2017 Jul; 146(1):27-33. PubMed ID: 28465008
[TBL] [Abstract][Full Text] [Related]
22. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
23. A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
Tran LKH; Tran PMH; Mysona DP; Purohit SB; Myers E; Lee WS; Dun B; Xu D; Liu H; Hopkins D; Nechtman J; Scelsi CL; Mittal PK; Kleven D; Wallbillich JJ; Rungruang B; Ghamande S; She JX
Gynecol Oncol; 2020 May; 157(2):340-347. PubMed ID: 32067813
[TBL] [Abstract][Full Text] [Related]
24. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
25. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
27. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
28. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
Ahmed Q; Hussein Y; Hayek K; Bandyopadhyay S; Semaan A; Abdul-Karim F; Al-Wahab Z; Munkarah AR; Elshaikh MA; Alosh B; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
Gynecol Oncol; 2014 Feb; 132(2):372-6. PubMed ID: 24262874
[TBL] [Abstract][Full Text] [Related]
29. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
30. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
de Jonge MM; Mooyaart AL; Vreeswijk MP; de Kroon CD; van Wezel T; van Asperen CJ; Smit VT; Dekkers OM; Bosse T
Eur J Cancer; 2017 Feb; 72():215-225. PubMed ID: 28049106
[TBL] [Abstract][Full Text] [Related]
31. A 4-gene signature predicts prognosis of uterine serous carcinoma.
Chen H; Li L; Qin P; Xiong H; Chen R; Zhang M; Jiang Q
BMC Cancer; 2021 Feb; 21(1):154. PubMed ID: 33579221
[TBL] [Abstract][Full Text] [Related]
32. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
Bischof K; Knappskog S; Stefansson I; McCormack EM; Trovik J; Werner HMJ; Woie K; Gjertsen BT; Bjorge L
BMC Cancer; 2018 Jun; 18(1):684. PubMed ID: 29940909
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors of Uterine Serous Carcinoma-A Multicenter Study.
Zhong X; Wang J; Kaku T; Wang Z; Li X; Wei L
Int J Gynecol Cancer; 2018 Jul; 28(6):1138-1144. PubMed ID: 29621127
[TBL] [Abstract][Full Text] [Related]
34. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.
Mishra SK; Crasta JA
Int J Gynecol Cancer; 2010 May; 20(4):537-41. PubMed ID: 20442586
[TBL] [Abstract][Full Text] [Related]
35. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
36. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.
Rabban JT; Zaloudek CJ
Pathology; 2007 Feb; 39(1):125-33. PubMed ID: 17365828
[TBL] [Abstract][Full Text] [Related]
37. Assessment of the differences in oncologic outcomes between patients with high-grade serous ovarian carcinoma and uterine serous carcinoma.
Kilic F; Ersak B; Cakir C; Yuksel D; Kilic C; Korkmaz V; Tokgozoglu N; Toptas T; Boran N; Kimyon Comert G; Ureyen I; Tasci T; Moraloglu Tekin O; Ustun Y; Turan T
J Obstet Gynaecol Res; 2024 Jan; 50(1):86-94. PubMed ID: 37854000
[TBL] [Abstract][Full Text] [Related]
38. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
39. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
40. Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.
Milner R; Wombwell H; Eckersley S; Barnes D; Warwicker J; Van Dorp E; Rowlinson R; Dearden S; Hughes G; Harbron C; Wellings B; Hodgson D; Womack C; Gray N; Lau A; O'Connor MJ; Marsden C; Kvist AJ
Virchows Arch; 2013 Mar; 462(3):269-79. PubMed ID: 23354597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]